Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer).

Next Previous
X
Search
Trial Profile

Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer).

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poly ICLC (Primary) ; Poly ICLC (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Liver cancer; Liver metastases; Malignant melanoma; Neuroendocrine carcinoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Jan 2014 Endpoints amended as reported by ClinicalTrials.gov
    • 11 Jan 2014 Planned End Date changed from 1 Oct 2009 to 1 Jul 2014 as reported by ClinicalTrials.gov
    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top